Who is sponsoring NCT05840926?

NCT05840926 is sponsored by Liaquat University of Medical & Health Sciences.

What drugs are being tested in NCT05840926?

Interventions in NCT05840926: Probiotic Streptococcus salivarius K12, No probiotic supplementation.

What condition does NCT05840926 study?

NCT05840926 studies Upper Respiratory Tract Infection.

Is NCT05840926 still recruiting?

NCT05840926 is currently completed. Last updated 3 May 2023.

Last reviewed 2023-05-03 · How we verify

NCT05840926: PUNK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Probiotic S. Salivarius K12 for the Prevention of Upper Respiratory Tract Infection in Nursery-age Children

Completed NA Last updated 3 May 2023

What this trial tests

NA trial testing Probiotic Streptococcus salivarius K12 in Upper Respiratory Tract Infection in 287 participants. Completed in 31 March 2023.

Timeline

5 January 2022

Primary endpoint
20 December 2022

31 March 2023

Quick facts

Lead sponsor	Liaquat University of Medical & Health Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	287
Start date	5 January 2022
Primary completion	20 December 2022
Estimated completion	31 March 2023
Sites	1 location across Pakistan

Drugs / interventions tested

Probiotic Streptococcus salivarius K12
No probiotic supplementation

Conditions studied

Upper Respiratory Tract Infection — all drugs for Upper Respiratory Tract Infection →

Sponsor

Liaquat University of Medical & Health Sciences

Who can join

Adults 1 to 3, any sex, with Upper Respiratory Tract Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this retrospective study is to assess the treatment benefits of probiotic Streptococcus salivarius K12 for the prevention of recurrent bacterial and viral infections of the pharynx, tonsils and ears in children under 3 years of age.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Liaquat University of Medical & Health Sciences trials

Trials by the same sponsor.

NCT07519616 — Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms · NA · not yet recruiting
NCT07536698 — Co-supplementation With Bifidobacterium Longum W11 and Colopectin for Maintenance Therapy in Children With Functional Co · NA · not yet recruiting
NCT07502807 — Effect of Neurofast® Supplementation on Anxiety and Cardiovascular Outcomes in the Psycho-Cardio Phenotype Adults · NA · not yet recruiting
NCT07494279 — Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phen · NA · not yet recruiting
NCT07474831 — Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05840926 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Liaquat University of Medical & Health Sciences
Last refreshed: 3 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05840926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing